Monday may have been a holiday, but New England’s tech and life sciences companies haven’t slowed down their deal making. We’ve had plenty of headlines of acquisitions, an IPO, and venture funding rounds for companies we’ve covered before and other not-so-familiar names.
—Expressor Software, a Burlington, MA-based integration software provider, raised $4.5 million in expansion capital funding. The money comes from existing Expressor investors Commonwealth Capital Ventures, Globespan Capital Partners, and Sigma Partners.
—Waltham, MA-based Xkoto, a maker of database virtualization software for businesses, confirmed that it had been acquired by business intelligence giant Teradata (NYSE: TDC). Xkoto, which raised a $3 million Series C round last year from GrandBanks Capital and GrowthWorks Canadian Fund, said the companies don’t plan to disclose the financial terms of the acquisition.
—OzVision Global, a maker of remote video platforms for surveillance and telecommunications companies, raised $4.9 million of a planned $6.7 million offering of debt that can be converted into equity. The Woburn, MA-based company is backed by Aviv Venture Capital and Kardan Communications.
—Tesaro, a new Boston biotech company that plans to develop and acquire cancer drugs and other oncology products, said it has pulled in $20 million in a Series A financing. The money comes from the company’s founders and New Enterprise Associates, which has reserved another $40 million to support Tesaro over time.
—Waltham-based drug developer Logical Therapeutics announced it had wrapped up a $16.9 million Series C financing, led by SV Life Sciences. Burrill & Co., Novo A/S, and Novitas Capital participated in the round, which we first covered when an SEC filing showed that the company pulled in $10 million.
—Thermo Fisher Scientific said it will acquire Fermentas International, a Canadian maker of life sciences research materials and diagnostic tools, for $260 million in cash. Waltham-based Thermo said it expects to roll Fermentas into its analytical technologies unit.
—Watertown, MA-based antibiotic developer Tetraphase Pharmaceuticals pulled in a $45 million Series C round, led by new investor Excel Venture Management. Tetraphase also received support from its existing backers CMEA Ventures, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners, and Skyline Ventures.The company has now raised a total of $80 million.
—SynapDx, a Waltham startup working on technology for early stage detection of autism, said it has pulled in a $9 million Series A round, thanks to Bain Capital, General Catalyst Partners, and North Bridge Venture Partners.
—Cambridge, MA-based car sharing service Zipcar filed for a $75 million initial public offering. Earlier this spring, the company acquired Streetcar, a U.K. service with a similar business model, and borrowed $70 million through a one-year credit facility to use for expanding its U.S. fleet. Zipcar boasts more than 400,000 members, and covers 13 cities.
—Boston-based Excel Venture Management and angel investors have pumped $2.3 million in seed funding to Snaptic, a San Francisco maker of the 3Banana note-taking app for iPhone and Android. Snaptic CEO Steve Brown told VentureWire that 3Banana’s ability to help users track fitness, diet, and health information caught the eye of Excel, an investment firm focused on healthcare companies.
—Covidien, a healthcare products company with headquarters in Mansfield, MA, announced it will buy Plymouth, MN-based medical devices firm ev3 (NASDAQ: EVVV), for $2.6 billion, or $22.50 per share in cash. Covidien (NYSE: COV) said it expects the deal to close by July 31.